RNS Number : 5353A
Concurrent Technologies PLC
26 September 2022
 

This announcement contains inside information

Concurrent Technologies PLC

(the "Company")

Interim Results for the six months ended 30 June 2022

 

Concurrent Technologies PLC (AIM: CNC), a world leading specialist in high-end embedded computer products for critical applications, announces its interim results for the six months to 30 June 2022 ("H1 2022").

 

Financial Performance

Component supply issues have delayed shipping of some of the Company's products, such that a proportion of expected H1 2022 revenues will be recognised in a later period. However, this is a short-term issue and in no way relates to the quality of the underlying business. Demand for the Company's products is higher than ever with a strong H1 order book (£14.2M) and record backlog (£20.3M).

·    Revenue of £7.4M (H1 2021: £9.3M) - reduced solely as a result of components supply issues

·    Gross profit of £3.7M (H1 2021: £5.1M)  

·    Gross margin of 50.4% (H1 2021: 54.3%) - reduced as the result of price increases of some components due to high demand and limited supply (-£0.3M against H1 revenue)

·    Operating profit of £0.1M (H1 2021: £1.6M) - predominantly driven by revenue/gross margin variance of -£1.4M; net costs increased by c£0.2M, in line with investment strategy

·    Profit before tax of £0.0M (H1 2021: £1.6M)

·    EPS of 0.75 pence (H1 2021: 2.09 pence)

·    Interim dividend suspended for H1 2022 (H1 2021: 1.15 pence per share)

·    Cash Balance (including cash deposits) as at 30 June 2022 of £9.3M (31st Dec 2021: £11.8M)

reduced due to lower cashflow from operations of £0.6M, and continued investment of £3M, in line with our strategy

R&D investment will continue into H2 2022 at a similar level as H1 2022

 

Operational Summary

·    Strong order intake of £14.2M as at 30 June 2022, with significant backlog of £20.3M compared to £15.6M backlog as at 30 June 2021, up 30%

·    Defence is largest market sector at 76% revenue

·    Global customer base is solid with exports generating 90% of revenue

·    R&D costs (talent, improved process & analysis, materials) have increased by 50% to £2.4M (H1 2021 £1.6M), in line with stated strategy to enhance the number of product releases per annum and reflect the more complex nature of our offerings

·    Three new products launched in H1 2022 and on track to launch eight new products during FY2022 (approx. double previous cadence)

·    Component shortages have been exceptionally challenging, causing a significant limitation to our ability to ship product

·    Major new order with a Fortune 500 medical company with a $2.3M purchase order in 2022 and similar sized orders anticipated for several years to come

·    Experienced leadership team fully in place

·    New office opened in Theale to attract and retain talent

·    20% increase in headcount, in line with strategy, to enhance new product delivery and support our path to growth

Miles Adcock, CEO of Concurrent Technologies, commented: "Short term component availability is resulting in constrained performance in FY2022, with limited visibility of exactly when it will ease.  However, order intake is strong, and would otherwise reflect in a solid improvement in revenues.  Order intake should strengthen further as strategic initiatives take effect in FY2023 and beyond. Post period end, total order intake has further strengthened to £20.8M, producing a current backlog of £24.2M as at 12 September 2022. After more than a full year now leading this business, I am even more confident in our ability to grow and develop a successful global enterprise." 

 

 

CHAIRMAN'S STATEMENT

Whilst it is clearly disappointing the component supply issue has impacted on our revenues and profitability in the first half of 2022, which will continue in the second half of the year, it is important not to lose sight of the improving underlying fundamentals of the business, demonstrated in our product development, new customers, order intake, backlog and management strength.  The component supply issues will ease and, although we can't be sure exactly when, when they do we are well positioned to benefit from all the underlying fundamentals highlighted, which will drive long term growth.

The cash position of the Company remains strong, which has allowed us to continue to invest in engineering and product development. The long term success of any technology company is bringing innovative new products to market first and that is, and will remain, our focus.

Given the strong balance sheet, paying an interim dividend out of historical retained earnings was considered.  However, paying dividends from current year earnings is an important discipline we wish to maintain. We are committed to paying a dividend and our shareholders will see the benefit of this as we drive growth in the coming years.

 

CHIEF EXECUTIVE'S REVIEW

Financial Summary

The Company has continued to operate in a very challenging environment in H1 2022. The global component shortage impacts the entire electronics sector and has had a significant impact on short term performance.  The delay in completing the full manufacture of certain products, and a consequent delay in their shipping, has resulted in deferred invoicing and a corresponding reduction in revenue in the period against the prior year by 20% to £7.4M (H1 2021: £9.3M).

It is important to note that the impacted revenue is delayed and not lost, and we continue to recognise an exceptional backlog. We have strong relationships with our customers and are driving the pace for delivery. It is recognised by the customer base that the issues are driven by external factors (which all our competitors are also facing).

Demand driven increase in the costs of some components has also resulted in a reduction in gross margin of c.7% from 54.3% to 50.4%.  Both revenue and gross margin impacts are solely driven by component shortages and are not a reflection of the quality of our underlying business.  We have delivered an unaudited profit before tax (PBT) of £0.0M (H1 2021: £1.6M), a net variance of -£1.6M, primarily caused by the reduction in revenue volume and gross margin, with underlying net costs having increased by £0.2M (as per strategy, this is predominantly driven by investment in talent).

The balance sheet remains strong with no debt and £9.3M of cash balances (including cash deposits) as at 30 June 2022 (31 December 2021: £11.8M). In response to the components shortage, there has been a substantial and carefully managed investment in additional inventory, with an increase of £2.8M, to £9.4M (H1 2021: £6.6M). As the global supply chain recovers, and components become available, revenue generation will accelerate as the business not only delivers normal run rate outputs, but also increases capacity to enable the processing of the now record backlog (£20.3M at 30th June 2022 compared to £15.6M at 30 June 2021).  Whilst the backlog is to some degree inflated due to the challenges of supply, it is important to note that FY2021 order intake was at a record level (£25.2M), and an order intake of £14.2M in H1 2022 puts the business on track to secure another very strong year of customer commitment.

 

Review of Operations

Despite the headwind generated by short term components shortages, the business is making good progress with operational improvement and implementation of the strategy.   

A refreshed leadership team is now complete, with the new CFO Kim Garrod, being the most recent joiner in May 2022.  We have also recruited additional talent across the organisation in engineering and sales, as well as fully implementing new functions such as HR and Legal/Commercial, growing our headcount from 99 to 118 in the last 12 months.

We have previously stated that it is imperative that we deliver more products to market in a timelier fashion. Having set the challenge of broadly doubling our cadence of new product releases to eight this year, we have indeed released three new products in the first half of 2022 and remain on track to achieve the objective of eight for the full year.  This is reflected in a 100% increase in the cost of capitalised R&D compared to H1 2021.

We said we would develop a Build to Print partner in the USA to better access that domestic market.  We have now qualified Nextek, based in Madison, Alabama.  The intent is to be able to offer to the market genuinely 'Assembled in the USA' products by the end of 2022.

In addition to designing and manufacturing single board computers, we committed to invest in developing a systems business.  Having recruited specialist experts during H1, and engaging in business development dialogue with potential partners and customers, we will secure initial contracts with new customers in H2 2022.  An example of another new customer relationship that we have developed is the $2.3M purchase order from a Fortune 500 medical sector business, with the opportunity for similar size purchase orders from the same customer for several years to come.

 

Current Trading & Outlook

With a record H1 backlog of £20.3M, and a record YTD Order In-take of £20.8M (as at 12 September 2022), the business is starting to benefit from the refreshed approach to operations and strategy.  We have transformed from primarily relying on end of life products in recent years, to four fifths of our orders this year being for our current and new products, which are exciting existing and new customers.  In addition to increased demand from the market, we have built increased capacity to deliver through additional shifts and a qualified build to print partner in the United States.  Whilst the challenge of securing semiconductor components is frustratingly constraining everyone's ability to ship completed product, we are well positioned for material growth as the situation resolves.

 

 

 

 

 

Condensed Consolidated Statement of Comprehensive Income

Unaudited interim results to 30th June 2022



Six months

 

Six months

 

Year

 



ended

 

ended

 

ended

 


Note

30/06/22

 

30/06/21

 

31/12/21

 

CONTINUING OPERATIONS

 

£

 

£

 

£

 

Revenue

 

    7,421,285


    9,315,839


  20,450,453


Cost of sales


    3,680,258


    4,255,669


    9,016,878


Gross profit

 

    3,741,027


    5,060,170


  11,433,575


Net operating expenses


    3,688,676


    3,439,699


    7,889,921


Group operating profit

 

         52,351


    1,620,471


    3,543,654


Interest Costs


       (26,930)


       (32,233)


       (61,679)


Finance income


          6,992


          3,696


          1,880


Other Income


                -  


                -  


                -  


Profit before tax

 

         32,413


    1,591,934


    3,483,855


Tax


     (518,890)


         56,559


       638,412


Profit for the period

 

       551,303


    1,535,375


    2,845,443










Other Comprehensive Income

 







Exchange differences on translating foreign operations

       100,789


       (19,626)


         23,894


Tax relating to components of other comprehensive income

                  -


                  -


                  -


Other Comprehensive Income for the period, net of tax

       100,789


       (19,626)


         23,894


Total Comprehensive Income for the period

 

       652,092


    1,515,749


    2,869,337










Profit for the period attributable to:

 







Equity holders of the parent


       551,303


    1,535,375


    2,845,443










Total Comprehensive Income attributable to:

 







Equity holders of the parent


       652,092


    1,515,749


    2,869,337










Earnings per share

 







Basic earnings per share

4

0.75p


2.09p


 3.88p










Diluted earnings per share

4

0.75p


2.09p


 3.88p










Adjusted earnings per share


0.75p


2.09p


 3.72p


 

 



 

CONDENSED CONSOLIDATED BALANCE SHEET

Unaudited interim results to 30th June 2022



As at

 

As at

 

As at

 


30/06/22

 

30/06/21

 

31/12/21

ASSETS

 

£

 

£

 

£

Non-current assets

 






Property, plant and equipment


    2,445,996


    1,735,125


    1,436,009

Intangible assets


    9,058,713


    7,333,105


    7,692,528

Deferred tax assets


          7,243


         88,455


         31,042

Other Financial Assets


                -  


                -  


                -  



  11,511,952


    9,156,685


    9,159,579

Current assets

 






Inventories


    9,460,432


    6,619,081


    6,425,436

Trade and other receivables


    3,460,344


    2,614,711


    2,988,633

Current tax assets


       597,086


       351,104


       330,748

Other Financial Assets


                -  


                -  


                -  

Cash and cash equivalents


    9,265,663


  12,386,445


  11,839,758



  22,783,525


  21,971,341


  21,584,575








Total assets

 

  34,295,476


  31,128,026


  30,744,154








LIABILITIES

 






Non-current liabilities

 






Deferred tax liabilities


    2,176,884


    1,638,947


    2,193,418

Trade and other payables (LT Lease)


       505,767


       518,919


       570,576

Long term provisions


         18,256


         18,256


         19,172



    2,700,907


    2,176,122


    2,783,166

Current liabilities

 






Trade and other payables


    7,119,058


    5,625,215


    4,196,272

Short term provisions


         18,256


         18,256


         19,300

Current tax liabilities


         15,779


         33,190


          4,817



    7,153,093


    5,676,661


    4,220,389








Total liabilities

 

    9,854,000


    7,852,783


    7,003,555








Net assets

 

  24,441,476


  23,275,243


  23,740,599








EQUITY

 






Capital and reserves

 






Share capital


       739,000


       739,000


       739,000

Share premium account


    3,699,105


    3,699,105


    3,699,105

Capital redemption reserve


       256,976


       256,976


       256,976

Cumulative translation reserve


          3,390


     (140,919)


       (97,399)

Profit and loss account


  19,743,006


  18,721,081


  19,142,917

Equity attributable to equity holders of the parent

  24,441,477


  23,275,243


  23,740,599








Total equity

 

  24,441,477


  23,275,243


  23,740,599

 



 

Condensed Consolidated Cash Flow Statement

 

Unaudited interim results to 30th June 2022

 

 


Six months

 

Six months

 

Year

 


ended

 

ended

 

ended

 


30/06/2022

 

30/06/2021

 

31/12/2021

 


£

 

£

 

£

Cash flows from operating activities

 






Profit before tax for the period


         32,413


    1,591,934


    3,483,855

Adjustments for:







Finance income       


         (6,992)


         (3,696)


         (1,880)

Finance costs


         26,930


         32,233


         61,679

Depreciation       


       121,589


         84,757


       288,560

Amortisation       


       627,395


       606,453


    1,234,655

Impairment loss       


                -  


       150,000


       570,812

Loss on disposal of property, plant and equipment (PPE)      

                -  


         28,778


         27,401

Share-based payment       


         48,785


         16,339


         12,963

Exchange differences       


       111,153


       (16,762)


         46,623

(Increase)/decrease in inventories       


   (3,034,996)


   (1,085,507)


     (891,862)

(Increase)/decrease in trade and other receivables       

     (471,711)


     (258,554)


     (632,476)

Increase/(decrease) in trade and other payables       

    2,920,826


    1,645,319


       330,735

Cash generated from operations


       375,392


    2,791,294


    4,531,065

Tax (paid)/received


       270,780


       (21,110)


       (40,274)

Net cash generated from operating activities


       646,172


    2,770,184


    4,490,791








Cash flows from investing activities

 






Interest received


          6,992


          3,696


          1,880

Cash placed on deposit


                -  


                -  


                -  

Purchases of property, plant and equipment (PPE)


   (1,124,354)


     (115,045)


     (185,879)

Proceeds from sale of PPE


                -  


                -  


          1,500

Purchases of intangible assets


   (1,993,577)


     (883,983)


   (2,124,529)

Net cash used in investing activities


   (3,110,939)


     (995,332)


   (2,307,028)








Cash flows from financing activities

 






Equity dividends paid


                -  


   (1,063,769)


   (1,907,447)

Repayment of leasing liabilities


       (64,809)


       (56,871)


     (117,613)

Interest paid


       (26,930)


       (32,233)


       (61,679)

Cash received from share issue


                -  


                -  


                -  

Purchase of treasury shares


                -  


                -  


                -  

Net cash used in financing activities


       (91,739)


   (1,152,873)


   (2,086,739)








Effects of exchange rate changes on cash and cash equivalents

       (17,589)


         (1,508)


       (23,240)








Net increase/(decrease) in cash

 

   (2,574,095)


       620,471


         73,784

Cash at beginning of period


  11,839,758


  11,765,974


  11,765,974

Cash at the end of the period


    9,265,663


  12,386,445


  11,839,758

 



 

 

 

 

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Unaudited interim results to 30th June 2022






Capital

 

Cumulative

 

Profit

 



Share

 

Share

 

redemption

 

translation

 

and loss

 

Total

 

capital

 

premium

 

reserve

 

reserve

 

account

 

Equity

 

£

 

£

 

£

 

£

 

£

 

£

Balance at 1 January 2021

       739,000


    3,699,105


       256,976


     (121,293)


  18,271,819


  22,845,607













Profit for the period

                -  


                -  


                -  


                -  


    1,535,375


    1,535,375

Exchange differences on translating foreign operations

                -  


                -  


                -  


       (19,626)


                -  


       (19,626)

Total recognised comprehensive income for the period

                -  


                -  


                -  


       (19,626)


    1,535,375


    1,515,749

Share-based payment

                -  


                -  


                -  


                -  


         16,339


         16,339

Deferred tax on share based payment

                -  


                -  


                -  


                -  


       (38,683)


       (38,683)

Dividends paid

                -  


                -  


                -  


                -  


   (1,063,769)


   (1,063,769)

Sale of  treasury shares

                -  


                -  


                -  


                -  


                -  


                -  

Issue of Ordinary shares

                -  


                -  


                -  


                -  


                -  


                -  

Balance at 30 June 2021

       739,000


    3,699,105


       256,976


     (140,919)


  18,721,081


  23,275,243













Total recognised comprehensive income for the period

                -  


                -  


                -  


                -  


    1,310,059


    1,310,059

Exchange differences on translating foreign operations

                -  


                -  


                -  


         43,520


                -  


         43,520

Total recognised comprehensive income for the period

                -  


                -  


                -  


         43,520


    1,310,059


    1,353,579

Share-based payment

                -  


                -  


                -  


                -  


         (3,376)


         (3,376)

Deferred tax on share based payment

                -  


                -  


                -  


                -  


       (41,169)


       (41,169)

Dividends paid

                -  


                -  


                -  


                -  


     (843,678)


     (843,678)

Sale of  treasury shares

                -  


                -  


                -  


                -  


                -  


                -  

Balance at 31 December 2021

       739,000


    3,699,105


       256,976


       (97,399)


  19,142,917


  23,740,599













Total recognised comprehensive income for the period

                -  


                -  


                -  


                -  


       551,303


       551,303

Exchange differences on translating foreign operations

                -  


                -  


                -  


       100,789


                -  


       100,789

Total recognised comprehensive income for the period

                -  


                -  


                -  


       100,789


       551,303


       652,092

Share-based payment

                -  


                -  


                -  


                -  


         48,785


         48,785

Deferred tax on share based payment

                -  


                -  


                -  


                -  


                 1


                 1

Dividends paid

                -  


                -  


                -  


                -  


                -  


                -  

Issue of ordinary shares

                -  


                -  


                -  


                -  


                -  


                -  

Sale of  treasury shares

                -  


                -  


                -  


                -  


                -  


                -  

Balance at 30 June 2022

       739,000


    3,699,105


       256,976


          3,390


  19,743,006


  24,441,477



 

NOTES TO THE INTERIM REPORT

1.    General information

The principal activity of the Group is design, manufacture and supply of innovative high-end embedded single board computers and complementary accessories aimed at a wide base of customers within the defence & aerospace, telecommunications, medical and other markets.

Concurrent Technologies PLC ("the Company") is the Group's ultimate parent company. It is incorporated and domiciled in Great Britain. Concurrent Technologioes PLC shares are listed on the Alternative Investment Market of the London Stock Exchange.

The Group's condensed consolidated interim financial statements are presented in pounds sterling (£), which is also the functional currency of the parent company.

These condensed consolidated interim financial statements, which are unaudited, have been approved for issue by the Board of Directors on 23rd September 2022.

The information relating to the six months ended 30th June 2022 is unaudited and does not constitute statutory accounts within the meaning of section 434 of the Companies Act 2006. The statutory accounts for the year ended 31st December 2021, prepared in accordance with IFRSs (International Financial Reporting Standards) as adopted by the European Union, have been reported on by the Group's auditors and delivered to the Registrar of Companies. The auditor's report was qualified, and this qualification will be addressed in the statutory accounts for 31st December 2022.

2.    Summary of significant accounting policies

 

2.1  Basis of preparation

 

These condensed consolidated interim financial statements are for the six months period ended 30th June 2022. They have been prepared in accordance with IAS 34 "Interim Financial Reporting". They do not include all of the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31st December 2021, which have been been prepared in accordance with adopted IFRSs.

The accounting policies applied and methods of computation are consistent with those of the annual financial statements for the year end 31st December 2021, as described in those financial statements. The accounting policies have been consistently applied to all the periods presented.

There are no new IFRSs or IFRIC interpretations that are effective for the first time for the financial period beginning on or after 1st January 2022 that would be expected to have a material impact on the results or financial position of the Group.

2.2  Going Concern

The Directors are satisfied that the Group has sufficient resources to continue in operation for the foreseeable future, a period of not less than 12 months from the date of this report. Accordingly the continue to adopt the going concern basis in preparing these condensed financial statements.

2.3  Taxation

Current tax expense is recognised in these condensed consolidated interim financial statements based on the estimated effective tax rates for the full year.

 

3.    Segmental reporting

The Directors consider that the Group is engaged in a single segment of business, being design, manufacture of high-end embedded computer products and that therefore, the Company has only a single operating segment. The key measure of performance used by the Board to assess the Group's performance is the Group's profit before tax, as calculated under IFRS, and therefore no reconciliation is required between the measure of profit or loss used by the Board and that contained in the condensed consolidated interim financial statements.

4.    Earnings per share

Basic earnings per share is calculated by dividing the profit attributable to ordinary equity holders for the period by the weighted average number of ordinary shares outstanding during the period.

Diluted earnings per share is calculated adjusting the weightesd average number of ordinary shares outstanding to assume conversion of all contracted dilutive potential ordinary shares. The Company only has one category of dilutive potential ordinary shares, namely share options.

                The inputs to earnings per share calculation are shown below:

 







Six months

 

Six months

 

Year

 






ended

 

ended

 

ended

 






30/06/22

 

30/06/21

 

31/12/21

 






£

 

£

 

£

Profit attributable to ordinary equity holders



       551,303


    1,535,375


    2,845,443


















Six months

 

Six months

 

Year

 






ended

 

ended

 

ended

 






30/06/22

 

30/06/21

 

31/12/21

 






 

 

 











Weighted average number of ordinary shares for basic earnings per share

  73,363,490


  73,673,490


  73,363,490

Adjustment for share options




                  -  





Weighted average number of ordinary shares for diluted earnings per share

  73,363,490


  73,673,490


  73,363,490

 

 

 

 

 

5.    Shareholder Communication

A copy of these condensed interim financial statements is available from the Company's Registered office at:

4 Gilberd Court,

Newcomen Way,

Colchester,

Essex, UK

CO4 9WN

They are also available from the Company's website at www.gocct.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR UVSORUUUKUAR
Anonymous (not verified) Interim Results 32985798 A Mon, 09/26/2022 - 07:00 LSE RNS Results and Trading Reports CNC